Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and <i>In Vitro</i> Assessment

<table>: (a) Dose-response cytotoxicity of DOX-loaded PEI-enhanced HSA nanoparticles as compared to free DOX administered to MCF-7 breast cancer cells in log-phase culture after 48 hrs of treatment with different concentrations of DOX. (b) Time of exposure: cytotoxicity resulting from DOX-loaded PEI-enhanced HSA nanoparticles versus free DOX over 96 hrs was measured. The concentration of DOX administered was 1 <i>μ</i>g/mL to MCF-7 breast cancer cells. Percentage of viable cells was assessed by an MTS assay and then compared to untreated cells in the control wells (mean ± S.D., <svg height="10.9125" id="M5" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 35.099998 10.9125" width="35.099998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.9125)">
<g transform="translate(72,-63.27)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">3</tspan>
</text>
</g>
</g>
</svg>).</table>

Journal of Drug Delivery

fig4

Figure 4

Figure 4: Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and <i>In Vitro</i> Assessment 

Journal of Drug Delivery

Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and In Vitro Assessment

Figure 4